bexarotene   Click here for help

GtoPdb Ligand ID: 2807

Synonyms: LGD1069 | Targretin® | Targrexin®
Approved drug PDB Ligand
bexarotene is an approved drug (FDA (1999), EMA (2001))
Compound class: Synthetic organic
Comment: Bexarotene is a retinoid that selectively activates retinoid X receptors (RXRs), and is used for its antineoplastic action.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: bexarotene

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 37.3
Molecular weight 348.21
XLogP 8.16
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Cc1cc2c(cc1C(=C)c1ccc(cc1)C(=O)O)C(C)(C)CCC2(C)C
Isomeric SMILES Cc1cc2c(cc1C(=C)c1ccc(cc1)C(=O)O)C(C)(C)CCC2(C)C
InChI InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
No information available.
Summary of Clinical Use Click here for help
Bexarotene is an antineoplastic agent used in the treatment of cutaneous T cell lymphoma, usually following failure of previous treatments. Bexarotene shows activity in all clinical stages of cutaneous T cell lymphoma and has been used for non-indicated cancers such as lung and breast cancer, and Kaposi’s sarcoma.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The mechanism of action is poorly understood but involves selective activation of retinoid X receptors (RXRα, RXRβ and RXRγ)